Hans Christinger is motivated by two factors: to make a meaningful difference in patients’ lives now; and to build a world-class company that will significantly impact those in need. He is passionate about pairing his in-depth experience as a dedicated leader, innovator and advocate across the life science community with Neurvati’s resources and mission to bring treatments to the patients who need them most.

Mr. Christinger has accumulated more than 30 years’ experience in the biopharmaceutical industry, including roles in business development, drug development and scientific research. He has a track record of leveraging strategic partnerships to build leading science-based, patient-centered companies in neurology and ophthalmology, as evidenced by his prior roles at Ovid Therapeutics and Ophthotech (Iveric). His success is enabled by his experience with, and network from global pharmaceutical companies Abbott and Roche, where he built business units, differentiated portfolios and capabilities through partnering. He is an active Board Member and Advisor to the KIF1A Foundation, Vice Chairperson for NYBIO’s Executive Committee and advises several early-stage biotechnology companies.

Mr. Christinger began his career as a bench scientist at Genentech where he authored 15 structural biology-related peer-reviewed papers. He earned a Master of Business Administration from Babson College, a Master of Science in chemistry from San Francisco State University and a Bachelor of Science in biochemistry from the University of Vermont.